| Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. | |
| | |
MedLine Citation:
|
PMID: 20430307 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The choice of therapeutic agents for patients with moderate-to-severe psoriasis has expanded significantly in the past decade. With new understanding of the immunologic basis of psoriasis, multiple new potential targets for therapy have been identified. It is likely that a series of new medications to focus on the newly identified pathways is on the horizon. The first pathway targeted by new medications focuses on the p40 subunit that is shared by interleukin (IL)-12 and IL-23. Two human anti-p40 antibodies have been used therapeutically in psoriasis to date, ustekinumab (CNTO-1275, Stelara, Centocor, Horsham, PA) and briakinumab (ABT-874, Abbott, Abbott Park, IL). Ustekinumab was recently approved by the United States Food and Drug Administration, making it the first medication approved in the United States to work by this pathway while briakinumab is currently in phase III clinical trials. |
| | |
Authors:
|
Mona Gandhi; Eihab Alwawi; Kenneth B Gordon |
Related Documents
:
|
17640927 - The aromatic cluster in kchip1b affects kv4 inactivation gating. 2120627 - Medical units: who should command? 19824527 - Show me the monet. 10681287 - Eugenic sterilization and a qualified nazi analogy: the united states and germany, 1930... 17647177 - Procedural skills: what's taught in medical school, what ought to be? 19541387 - New hospital disinfection processes for both conventional and prion infectious agents c... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Seminars in cutaneous medicine and surgery Volume: 29 ISSN: 1558-0768 ISO Abbreviation: Semin Cutan Med Surg Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-04-30 Completed Date: 2010-08-12 Revised Date: 2011-07-29 |
Medline Journal Info:
|
Nlm Unique ID: 9617260 Medline TA: Semin Cutan Med Surg Country: United States |
Other Details:
|
Languages: eng Pagination: 48-52 Citation Subset: IM |
Affiliation:
|
Division of Dermatology, NorthShore University HealthSystem, Skokie, IL 60077, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
pharmacology*,
therapeutic use Humans Immunologic Factors / therapeutic use* Interleukin-12 / antagonists & inhibitors* Interleukin-23 / antagonists & inhibitors* Psoriasis / drug therapy*, immunology, pathology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/Interleukin-23; 0/briakinumab; 0/ustekinumab; 187348-17-0/Interleukin-12 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Safety and efficacy of the tumor necrosis factor antagonists.
Next Document: Alefacept for psoriasis.